FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800528626> ?p ?o ?g. }

• W2800528626 abstract "Objective: To compare the efficacy of deflazacort vs prednisone/prednisolone in a posthoc meta-analysis of a phase 2b and phase 3 study. Background: Corticosteroids can slow the loss of motor function in patients with Duchenne muscular dystrophy (DMD) and are considered part of the standard of care. The phase 2b (Study 007) and phase 3 (ACT DMD) clinical trials of ataluren are the largest, randomized, double-blind, placebo-controlled studies in nonsense mutation DMD to date. Design/Methods: In a meta-analysis of the placebo arm of a phase 2b and phase 3 study, evidence comparing the efficacy of deflazacort vs prednisone/prednisolone was assessed post-hoc using the 6 minute walk test (6MWT) in patients with phenotypic and genotypic evidence of DMD aged ≥ 7 y, a baseline 6-minute walk distance (6MWD) ≥ 150 m, and ≤80% of predicted for their age and height. Patients in the placebo arms of each study received deflazacort (n=64) or prednisone/prednisolone (n=82) for 48 weeks after being on that same treatment for ≥12 months prior to the study start. The primary endpoint was change from baseline to week 48 in 6MWD. Safety parameters were also assessed. Results: The weighted estimate of the treatment differences in 6 MWD (m, ±SEM) is 34.1m ± 13.5m and 95% CI of 7.6 to 60.7, showing a significant difference (p=0.006) favoring deflazacort. Respective adverse events ≥10% for deflazacort or prednisone/prednisolone were: vomiting (21.9%, 19.5%) headache (18.8%, 20.7%), nasopharyngitis (12.5%, 24.4%), fall (14.1%, 18,3%) diarrhea (12.5%, 14.6%), upper abdominal pain (7.8%, 17.1%), cough (9.4%, 15.9%), pain in extremity (12.5%, 11.0%), pyrexia (9.4%, 12.2%). Conclusions: Deflazacort appeared to be more effective than prednisone/prednisolone in delaying progression of DMD. Study Supported by: PTC Therapeutics, Inc Disclosure: Dr. Riebling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics. Dr. O9Mara has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Elfring has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Luo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. McIntosh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics. Dr. McIntosh holds stock and/or stock options in PTC Therapeutics. Dr. Santos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Parsons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, AveXis, Sarepta. Dr. Parsons has received research support from Biogen, AveXis, PTC, Sarepta. Dr. Shieh has nothing to disclose. Dr. Apkon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Apkon has received research support from PTC, Sarepta, and Eli Lilly and Marathon Pharm. Dr. Campbell has nothing to disclose. Dr. McDonald has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC, Santhera, Sarepta, Catabasis, Mitobridge, Cardero, Capricor. Dr. McDonald has received research support from PTC, Sarepta, Santhera, Pfizer, Marathon." @default.
• W2800528626 created "2018-05-17" @default.
• W2800528626 creator A5001131087 @default.
• W2800528626 creator A5019504361 @default.
• W2800528626 creator A5024765873 @default.
• W2800528626 creator A5034764399 @default.
• W2800528626 creator A5043186708 @default.
• W2800528626 creator A5064897502 @default.
• W2800528626 creator A5070537902 @default.
• W2800528626 creator A5071163954 @default.
• W2800528626 creator A5076402259 @default.
• W2800528626 creator A5076897727 @default.
• W2800528626 creator A5082501640 @default.
• W2800528626 creator A5085418762 @default.
• W2800528626 creator A5089734098 @default.
• W2800528626 date "2018-04-10" @default.
• W2800528626 modified "2023-10-05" @default.
• W2800528626 title "Meta-Analysis of Deflazacort vs Prednisone/Prednisolone in Patients with Duchenne Muscular Dystrophy (P2.325)" @default.
• W2800528626 hasPublicationYear "2018" @default.
• W2800528626 type Work @default.
• W2800528626 sameAs 2800528626 @default.
• W2800528626 citedByCount "0" @default.
• W2800528626 crossrefType "journal-article" @default.
• W2800528626 hasAuthorship W2800528626A5001131087 @default.
• W2800528626 hasAuthorship W2800528626A5019504361 @default.
• W2800528626 hasAuthorship W2800528626A5024765873 @default.
• W2800528626 hasAuthorship W2800528626A5034764399 @default.
• W2800528626 hasAuthorship W2800528626A5043186708 @default.
• W2800528626 hasAuthorship W2800528626A5064897502 @default.
• W2800528626 hasAuthorship W2800528626A5070537902 @default.
• W2800528626 hasAuthorship W2800528626A5071163954 @default.
• W2800528626 hasAuthorship W2800528626A5076402259 @default.
• W2800528626 hasAuthorship W2800528626A5076897727 @default.
• W2800528626 hasAuthorship W2800528626A5082501640 @default.
• W2800528626 hasAuthorship W2800528626A5085418762 @default.
• W2800528626 hasAuthorship W2800528626A5089734098 @default.
• W2800528626 hasConcept C126322002 @default.
• W2800528626 hasConcept C142724271 @default.
• W2800528626 hasConcept C168563851 @default.
• W2800528626 hasConcept C203092338 @default.
• W2800528626 hasConcept C204787440 @default.
• W2800528626 hasConcept C27081682 @default.
• W2800528626 hasConcept C2776376305 @default.
• W2800528626 hasConcept C2776715498 @default.
• W2800528626 hasConcept C2778720950 @default.
• W2800528626 hasConcept C2778943923 @default.
• W2800528626 hasConcept C2779030066 @default.
• W2800528626 hasConcept C71924100 @default.
• W2800528626 hasConceptScore W2800528626C126322002 @default.
• W2800528626 hasConceptScore W2800528626C142724271 @default.
• W2800528626 hasConceptScore W2800528626C168563851 @default.
• W2800528626 hasConceptScore W2800528626C203092338 @default.
• W2800528626 hasConceptScore W2800528626C204787440 @default.
• W2800528626 hasConceptScore W2800528626C27081682 @default.
• W2800528626 hasConceptScore W2800528626C2776376305 @default.
• W2800528626 hasConceptScore W2800528626C2776715498 @default.
• W2800528626 hasConceptScore W2800528626C2778720950 @default.
• W2800528626 hasConceptScore W2800528626C2778943923 @default.
• W2800528626 hasConceptScore W2800528626C2779030066 @default.
• W2800528626 hasConceptScore W2800528626C71924100 @default.
• W2800528626 hasOpenAccess W2800528626 @default.
• W2800528626 hasRelatedWork W2800288795 @default.
• W2800528626 hasRelatedWork W2801706337 @default.
• W2800528626 hasRelatedWork W2802731780 @default.
• W2800528626 hasRelatedWork W2803651213 @default.
• W2800528626 hasRelatedWork W2803956198 @default.
• W2800528626 hasRelatedWork W2804412694 @default.
• W2800528626 hasRelatedWork W2806319173 @default.
• W2800528626 hasRelatedWork W2806923811 @default.
• W2800528626 hasRelatedWork W2808054523 @default.
• W2800528626 hasRelatedWork W2811297374 @default.
• W2800528626 hasRelatedWork W2885049414 @default.
• W2800528626 hasRelatedWork W2886472755 @default.
• W2800528626 hasRelatedWork W2893281143 @default.
• W2800528626 hasRelatedWork W2894489394 @default.
• W2800528626 hasRelatedWork W2994085278 @default.
• W2800528626 hasRelatedWork W3019112891 @default.
• W2800528626 hasRelatedWork W3043068731 @default.
• W2800528626 hasRelatedWork W3198538026 @default.
• W2800528626 hasRelatedWork W3208089793 @default.
• W2800528626 hasRelatedWork W3091630617 @default.
• W2800528626 hasVolume "90" @default.
• W2800528626 isParatext "false" @default.
• W2800528626 isRetracted "false" @default.
• W2800528626 magId "2800528626" @default.
• W2800528626 workType "article" @default.